Mylan, J&J Unit Reach Deal In Birth Control Drug Patent Row

Law360, New York (November 8, 2012, 5:15 PM EST) -- Mylan Inc. said Thursday that it had settled patent-infringement litigation launched by a Johnson & Johnson unit that will allow Mylan to sell a generic version of birth control drug Ortho Tri-Cyclen Lo starting Dec. 31, 2015.

The settlement ends Janssen Pharmaceuticals Inc.'s suit accusing Mylan and Indian generics maker Famy Care Ltd. — Mylan’s partner in marketing a generic version of Ortho Tri-Cyclen Lo in the U.S. — of filing abbreviated new drug applications with the U.S. Food and Drug Administration to produce and sell...
To view the full article, register now.